Compare KLAR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | TGTX |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.9B |
| IPO Year | 2023 | 2008 |
| Metric | KLAR | TGTX |
|---|---|---|
| Price | $14.29 | $54.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $38.00 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 6.3M | 2.3M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $28.56 | $49.08 |
| Revenue Next Year | $19.93 | $26.69 |
| P/E Ratio | ★ N/A | $323.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.06 | $26.76 |
| 52 Week High | $47.48 | $59.30 |
| Indicator | KLAR | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 57.45 |
| Support Level | $12.77 | $51.22 |
| Resistance Level | $15.30 | $58.08 |
| Average True Range (ATR) | 0.78 | 2.25 |
| MACD | -0.49 | 0.68 |
| Stochastic Oscillator | 9.78 | 67.83 |
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.